Clinical Trials Logo

Clinical Trial Summary

This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah. Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.


Clinical Trial Description

Among health care environments, ED often are the front lines of care for those with OUD or who experience opioid overdose. The University of Utah Hospital ED has the Bridge Program which provides buprenorphine and naloxone with warm-hand off referral for continued treatment to people presenting with OUD. In order to extend the services offered by the Bridge Program to rural hospitals, the investigators will be providing mentoring and education to Castleview Hospital in establishing a similar program. Castleview Hospital is the only acute care hospital that serves Carbon and Emery counties, which outside of the Salt Lake City metro area have the highest opioid overdose rates in the State of Utah. This project will utilize both quantitative and qualitative measures to evaluate the impact of this program on patients, hospital staff, and community members. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06087991
Study type Observational
Source University of Utah
Contact Jerry Cochran
Phone 801-213-0654
Email jerry.cochran@hsc.utah.edu
Status Recruiting
Phase
Start date April 1, 2023
Completion date October 1, 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04839978 - Community Trial in the Cherokee Nation N/A
Completed NCT05593341 - Opioid Education in Total Knee Arthroplasty N/A
Terminated NCT04495374 - Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy Phase 4
Terminated NCT03822962 - Pain Management Following Sinus Surgery Early Phase 1
Completed NCT03936985 - Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
Active, not recruiting NCT01740414 - Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers Phase 2
Completed NCT00499746 - The Discriminative Effects of Tramadol in Humans Phase 1/Phase 2
Completed NCT03684681 - The Navigator Trial N/A
Completed NCT04340622 - Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders N/A
Completed NCT04018664 - Oral Abuse Potential Study of Nalbuphine Phase 1
Completed NCT00699010 - Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse Phase 2
Recruiting NCT05006079 - Opioid/Benzodiazepine Polydrug Abuse: Aim 3 Phase 2
Completed NCT04710069 - Postoperative Opt-In Narcotic Treatment Study N/A
Terminated NCT03992079 - A Multimodal Enhanced Recovery Program in Anorectal Surgery N/A
Active, not recruiting NCT03570099 - Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications
Completed NCT02804152 - Program for Pain & Prescription Opioid Use in Pregnancy N/A
Active, not recruiting NCT01632982 - Mobile Psychosocial Interventions for MMT Clients N/A
Active, not recruiting NCT01136356 - A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals Phase 1/Phase 2
Not yet recruiting NCT05706311 - Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool N/A
Completed NCT03743493 - PCORnet Opioid Surveillance Study